Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
Kyriakos P PapadopoulosKaren AutioTalia GolanKonstantin DobrenkovElliot ChartashQiusheng ChenRichard WnekGeorgina V LongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
MK-4166 900 mg i.v. every 3 weeks as monotherapy and with pembrolizumab was tolerable. Responses were observed with combination therapy, mostly in patients with ICI-naïve melanoma.